ArticleLa Radiologia medica2021
Real-world clinical validity of cardiac magnetic resonance tissue tracking in primitive hypertrophic cardiomyopathy.
Article in La Radiologia medica, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Imaging of metabolic and overload disorders in tissues and organs.Japanese journal of radiology · 2023Review
- Practical Guide to Interpreting Cardiac Magnetic Resonance in Patients with Cardiac Masses.Journal of cardiovascular development and disease · 2023Review
- Cardiac magnetic resonance-derived tissue tracking strain in patients with hypertrophic cardiomyopathy.Quantitative imaging in medicine and surgery · 2023Article
- Gender Medicine in Clinical Radiology Practice.Journal of personalized medicine · 2023Review
- Heart Failure and Cardiomyopathies: CT and MR from Basics to Advanced Imaging.Diagnostics (Basel, Switzerland) · 2022Review
- Radiomics in medical imaging: pitfalls and challenges in clinical management.Japanese journal of radiology · 2022Review
- A Narrative Review on LI-RADS Algorithm in Liver Tumors: Prospects and Pitfalls.Diagnostics (Basel, Switzerland) · 2022Review
- Combined Hepatocellular-Cholangiocarcinoma: What the Multidisciplinary Team Should Know.Diagnostics (Basel, Switzerland) · 2022Review
- Unenhanced Cardiac Magnetic Resonance may improve detection and prognostication of an occult heart involvement in asymptomatic patients with systemic sclerosis.Scientific reports · 2022Article
- Stress Perfusion Cardiac Magnetic Resonance in Long-Standing Non-Infarcted Chronic Coronary Syndrome with Preserved Systolic Function.Diagnostics (Basel, Switzerland) · 2022Article
- An update on radiomics techniques in primary liver cancers.Infectious agents and cancer · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveCardiac magnetic resonance (CMR) is an uncontested diagnostic tool for identifying and assessing hypertrophic cardiomyopathy (HCM) patients. Concerning the necessity to identify valid prognosticators for predicting the individual risk of clinical evolution, this study aimed to evaluate the clinical validity of CMR tissue tracking (TT) analysis in patients affected by primitive HCM in a real-world setting.
methodsThis historical prospective study included 33 patients. Diagnostic validity and clinical validation were assessed for strain values. CMR-TT diagnostic validity was studied comparing HCM patients with healthy control groups and phenotypic presentation of HCM. The impact of strain values and all phenotypic disease characteristics were assessed in a long-term follow-up study.
resultsThe inter-reading agreement was good for all strain parameters. Significant differences were observed between the control group and HCM patients. Similarly, hypertrophic and LGE + segments showed lower deformability than healthy segments. The AUC of predictive model, including conventional risk factors for MACE occurrence and all strain values, reached 98% of diagnostic concordance (95% CI .94-1; standard error: .02; p value .0001), compared to conventional risk factors only (86%; 95% CI .73-99; standard error: .07; p value .002).
conclusionIn patients with primitive HCM, CMR-TT strain proves high clinical validity providing independent and non-negligible prognostic advantages over clinical features and traditional CMR markers.
Indexed as
Identifiers
34894317What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.